The new Danish-Norwegian study is the first study to document possible adverse events in relation to the COVID-19 vaccine Vaxzevria from AstraZeneca, in which all vaccine recipients have been followed systematically, as opposed to previous studies, which have relied primarily on reported adverse reactions.